FDA's Galleri Panel Delivers a Split Verdict — Here's What It Means for Labs
Short answer: On September 23, 2026, the FDA's Molecular and Clinical Genetics Panel cast three separate votes on GRAIL's Galleri multi-cancer early detection test: 7-2 (with one abstention) that benefits outweigh risks, a unanimous 10-0 on safety, and a split 6-4 on whether the evidence proves the test actually works for its intended population. The panel also recommended GRAIL stop marketing Galleri as an "early detection" tool. FDA is not bound by the vote and expects to issue a final decision within months.
Three Votes, Three Different Answers
The panel did not cast a single up-or-down vote on GRAIL's premarket approval (PMA) application for Galleri, a next-generation sequencing test that screens cell-free DNA for cancer-specific methylation signals in adults 50 and older. It voted on three distinct questions, and the answers diverged sharply. On whether Galleri's benefits outweigh its risks for the intended population, the panel voted 7-2 with one abstention in favor. On safety, the vote was unanimous, 10-0. But on the narrower question of whether the evidence provides reasonable assurance that the test is effective, the panel split 6-4 (Medical Daily; GRAIL press release via PR Newswire).
That gap matters more than any single headline number. A panel can find that a test is safe and that its overall benefit-risk balance is favorable while still not being convinced the underlying evidence proves the test does what its label claims. That is precisely the position four of ten panelists took on Galleri, and it is the vote most likely to shape how FDA writes any approval conditions.
Why Four Panelists Voted No on Effectiveness
The dissent centered on one voice in particular. Phil Castle, director of the National Cancer Institute's Division of Cancer Prevention, warned that "routine approval and broad population rollout would risk harm and waste resources," arguing the performance data were too premature to prove the test delivers clinical benefit and could create false reassurance in patients who test negative (Medical Daily). That concern echoes the gap FDA staff had already flagged before the meeting: Galleri's randomized controlled trial, NHS-Galleri, did not meet its primary endpoint of a statistically significant reduction in late-stage cancer diagnoses, and the test's stage I detection rate ran well below its stage IV detection rate in both major studies underlying the application.
The panel's discussion also produced a specific, actionable recommendation: that Galleri's marketing should stop describing the product as an "early detection" tool and should instead emphasize that it supplements, rather than replaces, guideline-recommended screening (Medical Daily). That recommendation runs directly counter to how GRAIL currently positions the product, and it is a preview of the kind of labeling condition FDA could attach if it approves the PMA.
What Happens Next
An advisory panel vote is a recommendation, not a decision. As GRAIL itself noted in its statement following the meeting, "the FDA convenes advisory committees to obtain independent expert advice" and "the agency is not bound by the Committee's recommendations." GRAIL CEO Josh Ofman called the outcome a reaffirmation of "a high evidence bar," while the company said FDA is expected to issue a final decision on the PMA "in the coming months," without naming a specific date (GRAIL press release via PR Newswire).
The regulatory stakes reach past one company. As we covered before the meeting, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, signed into law February 3, 2026, authorizes CMS to cover FDA-approved MCED tests with demonstrated clinical benefit, phased in starting at age 68. That law cannot activate for any product until a test actually clears FDA's premarket pathway — and today, every MCED test on the market, Galleri included, is sold as a laboratory-developed test outside that pathway. A split effectiveness vote does not block approval outright, but it raises the odds that any eventual clearance comes with tighter labeling conditions, a narrower indicated population, or post-market study requirements than GRAIL initially sought.
What Labs, Medical Directors, and RCM Teams Should Do Now
The split vote gives ordering teams and lab leadership several concrete things to track rather than wait on. First, if Galleri or a competing MCED product does clear FDA review, expect labeling language to more closely mirror the panel's framing — "may be used alongside," not "in place of," guideline-recommended screening — and expect payers to lean on that exact language when writing medical policy. Second, the effectiveness dissent focused on stage I sensitivity and the unmet late-stage-reduction endpoint; any lab counseling patients on MCED testing today, LDT or otherwise, should be prepared to walk through those same limitations rather than waiting for a payer denial to surface them. Third, watch for CPT/PLA code activity tied to any approved MCED test — a distinct, priced code is typically a prerequisite for consistent claims adjudication, and coding teams that get ahead of it will spend less time on appeals later. Finally, remember that FDA approval and Medicare coverage are two separate clocks: even a favorable PMA decision in the coming months would not, by itself, start MCED reimbursement, which under current law cannot begin before 2028 and only for a narrow, aging-in population.
For the fuller regulatory backdrop — GRAIL's evidence package, the performance data FDA staff flagged before the meeting, and how the Medicare MCED coverage law is structured — see our earlier coverage of the FDA's pre-vote review of the Galleri application. For how CMS evaluates genetic and molecular tests for coverage more broadly, our Medicare coverage guide for genetic testing covers the NCD, LCD, and MolDX framework this MCED pathway will eventually intersect with. And if your lab is already navigating payer pushback on newer test categories, our breakdown of why genetic testing claims get denied covers documentation patterns that hold up under review. ScreenMyGene tracks coverage and regulatory developments like this one as they unfold, so ordering teams aren't caught off guard by a policy shift.
Frequently Asked Questions
Did the FDA approve the Galleri test?
No. The September 23, 2026 meeting was an advisory panel vote, not an FDA decision. The panel recommended in favor of Galleri's benefit-risk profile 7-2 with one abstention and was unanimous on safety, but split 6-4 on effectiveness. FDA is not bound by these votes and is expected to issue its own decision on GRAIL's premarket approval application in the coming months.
Why did the panel split on effectiveness but not on safety or benefit-risk?
Panelists who voted no on effectiveness, including NCI's Phil Castle, argued the evidence was too premature to prove clinical benefit, citing Galleri's unmet late-stage-reduction endpoint in the NHS-Galleri trial and its lower detection rate for stage I cancers. The safety and overall benefit-risk votes did not turn on that same evidence gap.
What did the panel recommend about how Galleri is marketed?
The panel recommended that Galleri's marketing avoid describing it as an "early detection" tool and instead emphasize that patients should continue routine, guideline-recommended cancer screenings alongside it — a recommendation that conflicts with GRAIL's current marketing language.
Does this vote affect Medicare coverage for multi-cancer screening tests?
Not directly or immediately. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act requires FDA approval before CMS coverage can begin, with coverage phased in starting at age 68 no earlier than 2028. A split advisory vote does not change that law, but it may influence what conditions, if any, FDA attaches to an eventual approval.
Can labs still offer multi-cancer screening tests while this PMA is pending?
Yes. Galleri and similar multi-cancer screening products currently on the market are offered as laboratory-developed tests (LDTs), a separate regulatory pathway from FDA premarket approval. That status is unaffected by the pending PMA decision unless and until FDA rules on it.
This article is intended for laboratory professionals, medical directors, genetic counselors, and revenue cycle teams as general regulatory and policy information. It is not clinical, legal, or coding advice for any specific patient, payer contract, or claim. Confirm current FDA status, CMS coverage policy, and payer-specific requirements directly with the relevant agency or payer before making coverage or billing decisions.
Sources: GRAIL, Inc. press release via PR Newswire; Medical Daily reporting on the September 23, 2026 FDA Molecular and Clinical Genetics Panel meeting; FDA.gov Advisory Committee Calendar; Congress.gov (H.R. 7148, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act).